Long-term benefits of TUMT (transurethral microwave thermotherapy) unproven, says Swedish council
This article was originally published in Clinica
Although scientific documentation for the short-term effects of high energy transurethral microwave thermotherapy (TUMT) in the treatment of benign prostate hypertrophy (BPH) exists, few studies have been carried out on long-term benefits to patients, claims a new report by the Swedish council on technology assessment in health care (SBU). In addition to this, there has been no cost analysis of high energy TUMT in comparison with other treatment methods, says SBU in an alert issued last week.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.